Last updated: February 22, 2026
Is the Drug Registered and What Is Its Intended Use?
NDC 60219-2045 corresponds to Imatinib Mesylate, marketed as Gleevec/Glivec, primarily used for chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and other malignancies. Imatinib is a targeted kinase inhibitor with broad indications in oncology.
Current Market Landscape
Market Size and Disease Prevalence
- Prevalence of CML: Approximately 100,000 patients globally.
- Market penetration: Dominated by Gleevec with over 70% market share in CML treatment.
Key Competitors
| Product |
Market Share |
Price per 400 mg tablet |
Regulatory Status |
| Gleevec (Novartis) |
70% |
$10.00 |
FDA-approved, patent protected |
| Tasigna (Novartis) |
15% |
$15.00 |
FDA-approved, patent protected |
| Sprycel (BMS) |
10% |
$11.00 |
FDA-approved |
| Generic Imatinib |
5% |
$2.50 - $4.00 |
FDA-approved, patent expired |
Patent and Regulatory Status
- Patent expiration: Gleevec's US patent expired in 2016, leading to increased generic options.
- FDA approval: Imatinib remains approved for multiple indications; generics are approved since 2017.
Pricing Trends
- Branded drugs: Consistently priced between $8 to $11 per tablet in the U.S.
- Generic versions: Price reductions of 60-75% compared to branded.
Price Projection Factors
Patent and Market Entry
- Patent expirations enable generics, which drive prices downward.
- Price erosion observed since 2016 with increased availability of generics.
Manufacturing and Distribution
- Production costs for generics reduce unit prices.
- Distribution channels shifting toward biosimilars and less regulated markets.
Regulatory and Policy Changes
- Increased price transparency and importation policies may impact prices.
- Use of biosimilars is subject to regional regulatory pathways that influence the affordability landscape.
Forecasted Price Trajectory (Next 5 Years)
| Year |
Estimated Price per 400 mg Tablet |
Notes |
| 2023 |
$2.50 – $4.00 |
Dominance of generics, price stabilization |
| 2024 |
$2.20 – $3.50 |
Continued market penetration of generics |
| 2025 |
$2.00 – $3.00 |
Increased adoption, potential new biosims |
| 2026 |
$1.80 – $2.50 |
Price erosion plateau, regional discounts emerge |
| 2027 |
$1.50 – $2.00 |
Market saturation, biosimilar uptake accelerates |
Regional Variability
- United States: Prices tend toward the higher end due to regulatory reimbursement structures.
- Europe: Slightly lower prices owing to negotiated drug formularies.
- Emerging Markets: Prices rarely exceed $1.50 per tablet due to price controls and access programs.
Implications for Stakeholders
- R&D: Market expansion relies on indications beyond CML, such as uncommon cancers.
- Investors: Patent expiries indicate declining profits for branded Gleevec but increased sales for generics.
- Healthcare Providers: Cost reduction favors broader access but raises concerns about safety and bioequivalence.
Summary
NDC 60219-2045, corresponding to imatinib, is transitioning from branded dominance to generic proliferation. Prices are projected to decline steadily over the next five years, facilitated by patent expiries, increased generic manufacturing, and regional pricing policies. Pricing differences across regions reflect regulatory environments and market maturity.
Key Takeaways
- Imatinib’s market is consolidating with generics now accounting for a significant share.
- Prices are expected to fall below $2 per 400 mg tablet in most markets by 2027.
- Patent expiration in 2016 led to a dramatic price decline; this trend is ongoing.
- Entry of biosimilars and biosimilar-like products could further influence prices.
- Market growth hinges on expanding indications and overcoming regional access barriers.
FAQs
1. How has patent expiration affected imatinib prices?
Patent expiration in 2016 led to an influx of generics, reducing prices by up to 75%.
2. What are the main competitors for imatinib?
Generic imatinib, Tasigna, and Sprycel are key alternatives, with generics gaining market share.
3. Will prices stabilize or continue declining?
Prices are projected to decline gradually, approaching a plateau as generic markets mature.
4. How do regional policies influence pricing?
Price controls in emerging markets and negotiated formularies in Europe result in lower prices compared to the US.
5. What factors could disrupt current price trends?
Emerging biosimilars, regulatory changes, or new indications could alter the pricing landscape.
References
[1] U.S. Food and Drug Administration. (2017). Imatinib mesylate: Approval history. Retrieved from https://www.fda.gov
[2] MarketWatch. (2022). Imatinib market analysis and pricing trends.
[3] IMS Health. (2021). Global oncology drug market report.
[4] Novartis. (2021). Gleevec patent expiry and market impact.
[5] European Medicines Agency. (2022). Biosimilar regulation and market entry.
